Financial Contrast: 111 (NASDAQ:YI) versus Tempus AI (NASDAQ:TEM)

Tempus AI (NASDAQ:TEM) and 111 (NASDAQ:YI) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, dividends, institutional ownership and earnings.

Profitability

This table compares Tempus AI and 111’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Tempus AI	-17.77%	-50.28%	-10.33%
111	-1.01%	N/A	-4.86%

Risk and Volatility

Tempus AI has a beta of 3.54, indicating that its share price is 254% more volatile than the S&P 500. Comparatively, 111 has a beta of 0.67, indicating that its share price is 33% less volatile than the S&P 500.

Insider and Institutional Ownership

24.2% of Tempus AI shares are owned by institutional investors. Comparatively, 21.3% of 111 shares are owned by institutional investors. 24.3% of Tempus AI shares are owned by insiders. Comparatively, 43.9% of 111 shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Tempus AI and 111″s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tempus AI	$1.27 billion	10.21	-$245.03 million	($1.44)	-49.99
111	$10.48 billion	0.00	-$9.65 million	($1.60)	-1.93

111 has higher revenue and earnings than Tempus AI. Tempus AI is trading at a lower price-to-earnings ratio than 111, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Tempus AI and 111, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tempus AI	2	9	11	0	2.41
111	1	0	0	0	1.00

Tempus AI presently has a consensus price target of $71.05, suggesting a potential downside of 1.29%. Given Tempus AI’s stronger consensus rating and higher possible upside, analysts plainly believe Tempus AI is more favorable than 111.

About Tempus AI

Tempus AI Inc. is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. Tempus AI Inc. is based in CHICAGO.

About 111

111, Inc. engages in the provision of pharmaceutical products and medical services through online retail pharmacy and indirectly through offline pharmacy network. It operates through the B2C and B2B segments. The B2C segment engages in the sale of pharmaceutical and other health and wellness products directly to consumers through 1 Drugstore and its offline pharmacies. The B2B segment includes the sale of pharmaceutical products to pharmacy customers through 1 Drug Mall. The company was founded by Gang Yu and Jun Ling Liu in May 2013 and is headquartered in Shanghai, China.